Letermovir is an antiviral active pharmaceutical ingredient used to prevent cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those undergoing allogeneic stem cell transplants. It is a research compound developed for pharmaceutical manufacturing and supply.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Letermovir?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Triacetylganciclovir
pharmaceutical raw material
Inosine pranobex
pharmaceutical raw material
Foscarnet
pharmaceutical raw material
Acyclovir alaninate
pharmaceutical raw material
Cefdinir
pharmaceutical raw material
Vemurafenib
pharmaceutical raw material
Lithium citrate
pharmaceutical raw material
Phenothiazine
pharmaceutical raw material
The international HS code for Letermovir (CAS 917389-32-3) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
FWYSMLBETOMXAG-QHCPKHFHSA-N
COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
Sourcing Letermovir?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.